Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CTSA | P10619 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689312 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BCTSAS1PR3CYP26A1 | |
| SCHEMBL16689353 | 0.89 | CYP26A1 (0.46) | CTSAS1PR3CYP26A1ITGB1ITGA4 | |
| SCHEMBL17697902 | 0.89 | CYP26A1 (0.46) | CTSAS1PR3CYP26A1ITGB1ITGA4 | |
| SCHEMBL19283535 | 0.89 | CTSS (0.43) | ITGB3ITGA2BCTSAS1PR3CYP26A1 | |
| SCHEMBL20139043 | 0.88 | POLB (0.49) | CTSAPOLBAAK1 | |
| SCHEMBL21271453 | 0.88 | POLB (0.49) | CTSAPOLBAAK1 | |
| SCHEMBL20907724 | 0.87 | AAK1 (0.41) | S1PR3CTSSCTSKPOLBAAK1 | |
| SCHEMBL5662378 | 0.87 | AAK1 (0.41) | S1PR3CTSSCTSKPOLBAAK1 | |
| SCHEMBL22805510 | 0.86 | APP (0.42) | ITGB3ITGA2BS1PR3CTSSCTSK | |
| SCHEMBL29582295 | 0.86 | APP (0.42) | ITGB3ITGA2BS1PR3CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-6326372-B1 | BENIGN PROSTATE HYPERPLASIA | MERCK & CO., INC. | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | TNNI3, NME4, TNNT2 | ITGB3 4507/4885ITGA2B 4687/4885CTSA 4383/4885 |
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | ITGB3 2529/4885ITGA2B 3963/4885CTSA 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.